Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

NCT07227012 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07227012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
October 17, 2028
Enrollment
138 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, carcinoma, hepatocellular, hepatocellular cancer, hepatocellular carcinoma, liver neoplasms, metastatic hepatocellular carcinoma, unresectable hepatocellular carcinoma